Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Magerl

Showing results (121-130 of 152) with videos related to

Pageof 16
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|August 21, 2023
Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CUREThomas Buttgereit, Carolina Vera, Felix Aulenbacher, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
The New England Journal of Medicine|June 15, 2026
Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary AngioedemaDanny M Cohn, Padmalal Gurugama, Hilary J Longhurst, et al.
The Journal of Allergy and Clinical Immunology|May 28, 2021
Consensus on treatment goals in hereditary angioedema: A global Delphi initiativeMarcus Maurer, Emel Aygören-Pürsün, Aleena Banerji, et al.
Lancet (London, England)|March 3, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialTimothy J Craig, Avner Reshef, H Henry Li, et al.
Allergy|July 24, 2024
Disease modification in chronic spontaneous urticariaMarcus Maurer, Pavel Kolkhir, Manuel P Pereira, et al.
Lancet (London, England)|February 11, 2023
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trialEmel Aygören-Pürsün, Andrea Zanichelli, Danny M Cohn, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trialEmel Aygören-Pürsün, Marcin Stobiecki, Anna Valerieva, et al.
The New England Journal of Medicine|July 26, 2018
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary AngioedemaEmel Aygören-Pürsün, Anette Bygum, Vesna Grivcheva-Panovska, et al.
Allergy|January 30, 2026
International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary AngioedemaHenriette Farkas, Inmaculada Martinez-Saguer, Konrad Bork, et al.
Pageof 16

Showing results (121-130 of 152) with videos related to

Sort By:
Pageof 16
The Journal of Allergy and Clinical Immunology. in Practice|August 21, 2023
Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CUREThomas Buttgereit, Carolina Vera, Felix Aulenbacher, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
The New England Journal of Medicine|June 15, 2026
Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary AngioedemaDanny M Cohn, Padmalal Gurugama, Hilary J Longhurst, et al.
The Journal of Allergy and Clinical Immunology|May 28, 2021
Consensus on treatment goals in hereditary angioedema: A global Delphi initiativeMarcus Maurer, Emel Aygören-Pürsün, Aleena Banerji, et al.
Lancet (London, England)|March 3, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialTimothy J Craig, Avner Reshef, H Henry Li, et al.
Allergy|July 24, 2024
Disease modification in chronic spontaneous urticariaMarcus Maurer, Pavel Kolkhir, Manuel P Pereira, et al.
Lancet (London, England)|February 11, 2023
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trialEmel Aygören-Pürsün, Andrea Zanichelli, Danny M Cohn, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trialEmel Aygören-Pürsün, Marcin Stobiecki, Anna Valerieva, et al.
The New England Journal of Medicine|July 26, 2018
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary AngioedemaEmel Aygören-Pürsün, Anette Bygum, Vesna Grivcheva-Panovska, et al.
Allergy|January 30, 2026
International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary AngioedemaHenriette Farkas, Inmaculada Martinez-Saguer, Konrad Bork, et al.
Pageof 16